Exploration of various administration routes for the nitric oxide donating organic nitrite, nitrosooxypropanol, in a porcine model
5 affiliations
- 1School of Medical Sciences, Örebro University, Örebro, Sweden
- 2Department of Cardiothoracic and Vascular Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
- 3Department of Anesthesiology and Intensive Care, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
- 4Department of Physiology and Pharmacology, Section of Pharmacology, Karolinska Institutet, Stockholm, Sweden
- 5Attgeno AB, Stockholm, Sweden
Abstract
Organic nitrites are restricted to intravenous or inhaled administration. The aim was to explore novel administration routes for an organic nitrite, previously demonstrated to have pulmonary selectivity, in normal and elevated pulmonary vascular resistance. Hemodynamic and respiratory variables, including fraction of exhaled nitric oxide (FeNO), were measured in 13 anesthetized pigs. In naïve conditions, nitrosooxypropanol (PDNO) was given subcutaneously (100–1600 nmol/kg/min; 5 min/dose, 30 min interval), intramuscularly (50–400 nmol/kg/min; 5 min/dose, 30 min interval), intravenously (5–80 nmol/kg/min; 30 min infusion), intranasally (500–2000 nmol/kg boli), and sublingually (80–16,240 nmol/kg boli). In pulmonary hypertension (intravenous infusion of U46619), PDNO was given intravenously (5–45 nmol/kg/min; 15–20 mins infusion/dose) and subcutaneously (200–1800 nmol/kg/min; 5 min/dose at 20 min interval). Recovery was calculated using FeNO. PDNO, given by all administration routes, dose-dependently decreased systemic blood pressure and increased FeNO. Subcutaneous and intramuscular administration induced slow-onset (9 min to maximum effect) and long-lasting effects (~30 min). Intravenous administration induced rapid effects (1–2 min to steady state) and prompt decline after infusion cessation. The proportion of PDNO reaching exhaled gas (intravenous administration as reference; FeNO-based recovery) was 17% (intramuscularly) and 9% (subcutaneously). In pulmonary hypertension, intravenous and subcutaneous administration decreased the pulmonary/systemic vascular resistance-ratio. In this exploratory proof-of-concept study evaluating novel administration routes for organic nitrites, PDNO demonstrated measurable biological effects and acceptable FeNO-based recovery following intramuscular and subcutaneous administration. Furthermore, intranasal and tentatively sublingual administration showed biological effects. Future work on formulation and investigations into relevant disease models is warranted.
Related
- A nitric oxide donating β-elemene derivative induces reactive oxygen species associated apoptosis and reduces STAT3 phosphorylation in medulloblastoma cells
- Gastric lipase and PLRP2 trigger the activity of pancreatic lipase on various emulsions stabilized by phospholipids and galactolipids
- Dietary and Fluid-Intake Habits in Patients with Various Types of Urinary Incontinence: A Preliminary Study
- Right Versus Left Ventricular Myofiber Orientation in Various Congenital Heart Diseases Analyzed with X-Ray Phase-Contrast Tomography
- Unraveling the Lifespan Trajectory of White Matter Hypointensity on T1-weighted MR Images and Clinical Application in Various Brain Disorders
BibTeX
@article{hallerback2026exploration,
title = {{Exploration of various administration routes for the nitric oxide donating organic nitrite, nitrosooxypropanol, in a porcine model}},
author = {Anna Stene Hallerbäck and Måns Edström and Per Agvald and Kristofer F. Nilsson},
journal = {Drug Delivery},
year = {2026},
month = nov,
doi = {10.1080/10717544.2026.2752663},
url = {https://doi.org/10.1080/10717544.2026.2752663},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Exploration of various administration routes for the nitric oxide donating organic nitrite, nitrosooxypropanol, in a porcine model
AU - Anna Stene Hallerbäck
AU - Måns Edström
AU - Per Agvald
AU - Kristofer F. Nilsson
PY - 2026
DA - 2026/11/04
JO - Drug Delivery
DO - 10.1080/10717544.2026.2752663
UR - https://doi.org/10.1080/10717544.2026.2752663
AB - Organic nitrites are restricted to intravenous or inhaled administration. The aim was to explore novel administration routes for an organic nitrite, previously demonstrated to have pulmonary selectivity, in normal and elevated pulmonary vascular resistance. Hemodynamic and respiratory variables, including fraction of exhaled nitric oxide (FeNO), were measured in 13 anesthetized pigs. In naïve conditions, nitrosooxypropanol (PDNO) was given subcutaneously (100–1600 nmol/kg/min; 5 min/dose, 30 min interval), intramuscularly (50–400 nmol/kg/min; 5 min/dose, 30 min interval), intravenously (5–80 nmol/kg/min; 30 min infusion), intranasally (500–2000 nmol/kg boli), and sublingually (80–16,240 nmol/kg boli). In pulmonary hypertension (intravenous infusion of U46619), PDNO was given intravenously (5–45 nmol/kg/min; 15–20 mins infusion/dose) and subcutaneously (200–1800 nmol/kg/min; 5 min/dose at 20 min interval). Recovery was calculated using FeNO. PDNO, given by all administration routes, dose-dependently decreased systemic blood pressure and increased FeNO. Subcutaneous and intramuscular administration induced slow-onset (9 min to maximum effect) and long-lasting effects (~30 min). Intravenous administration induced rapid effects (1–2 min to steady state) and prompt decline after infusion cessation. The proportion of PDNO reaching exhaled gas (intravenous administration as reference; FeNO-based recovery) was 17% (intramuscularly) and 9% (subcutaneously). In pulmonary hypertension, intravenous and subcutaneous administration decreased the pulmonary/systemic vascular resistance-ratio. In this exploratory proof-of-concept study evaluating novel administration routes for organic nitrites, PDNO demonstrated measurable biological effects and acceptable FeNO-based recovery following intramuscular and subcutaneous administration. Furthermore, intranasal and tentatively sublingual administration showed biological effects. Future work on formulation and investigations into relevant disease models is warranted.
SN - 1071-7544
SN - 1521-0464
ER -